Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Proliferative Vitreoretinopathy (PVR) - Overview
Proliferative Vitreoretinopathy (PVR) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development
Aldeyra Therapeutics Inc
Aptitude Medical Systems Inc
Focal Point Pharmaceuticals Inc
Novartis AG
Pag Pharma Inc
Proliferative Vitreoretinopathy (PVR) - Drug Profiles
Aptamers to Inhibit PDGF for Proliferative Vitreoretinopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methotrexate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPP-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XOMA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proliferative Vitreoretinopathy (PVR) - Dormant Projects
Proliferative Vitreoretinopathy (PVR) - Product Development Milestones
Featured News & Press Releases
Jun 15, 2020: Aldeyra Therapeutics receives orphan medicil product desigtion from the European Commission for ADX-2191 Retil Disease Program
Apr 15, 2020: Tetra receives FDA Orphan Drug Desigtion for its ophthalmic clinical program
Feb 24, 2020: Aldeyra Therapeutics provides update on its proliferative vitreoretinopathy drug candidate at 2020 Research & Development Day
Dec 20, 2019: Aldeyra Therapeutics enrols first patient in Phase III GUARD study
Sep 24, 2019: Aldeyra Therapeutics receives Fast Track Desigtion for ADX-2191 for the prevention of Proliferative Vitreoretinopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Proliferative Vitreoretinopathy (PVR), 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Proliferative Vitreoretinopathy (PVR), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Proliferative Vitreoretinopathy (PVR) - Pipeline by Aldeyra Therapeutics Inc, 2021
Proliferative Vitreoretinopathy (PVR) - Pipeline by Aptitude Medical Systems Inc, 2021
Proliferative Vitreoretinopathy (PVR) - Pipeline by Focal Point Pharmaceuticals Inc, 2021
Proliferative Vitreoretinopathy (PVR) - Pipeline by Novartis AG, 2021
Proliferative Vitreoretinopathy (PVR) - Pipeline by Panag Pharma Inc, 2021
Proliferative Vitreoretinopathy (PVR) - Dormant Projects, 2021